Risk factors for abnormal liver function tests in patients with ileal pouch-anal anastomosis for underlying inflammatory bowel disease

American Journal of Gastroenterology

Volumn 104, Issue 10, 2009, Pages 2467-2475

  Navaneethan, Udayakumar ^a   Remzi, Feza H ^a   Nutter, Benjamin ^a   Fazio, Victor W ^a   Shen, Bo ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BILIRUBIN; CIPROFLOXACIN; IMMUNOMODULATING AGENT; MERCAPTOPURINE; METRONIDAZOLE; RIFAXIMIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ALKALINE PHOSPHATASE BLOOD LEVEL; ANASTOMOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE DISEASE; BILIRUBIN BLOOD LEVEL; BODY MASS; CHOLESTASIS; COLON RESECTION; CONTROLLED STUDY; CROHN DISEASE; DATA BASE; DISEASE DURATION; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENTERITIS; FAMILY HISTORY; FATTY LIVER; FEMALE; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ILEITIS; ILEUM POUCH ANUS ANASTOMOSIS; INTESTINE SURGERY; LIVER FUNCTION TEST; LIVER GRAFT REJECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SMOKING HABIT; ULCERATIVE COLITIS; CHI SQUARE DISTRIBUTION; COLON POUCH; LIVER DISEASE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY;

ANASTOMOSIS, SURGICAL; CHI-SQUARE DISTRIBUTION; COLONIC POUCHES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 70350507278     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.343     Document Type: Article

References (31)

1. Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine 1976; 55:401-412
2. Aadland E, Schrumpf E, Fausa O et al. Primary sclerosing cholangitis: a long-term follow-up study. Scand J Gastroenterol 1987; 22:655-664 (Pubitemid 17134654)
3. de Dombal FT, Goldie W, Watts JMcK et al. Hepatic histological changes in ulcerative colitis. Scand J Gastroenterol 1966; 1:220-227
4. Akwari O, van Heerden JA, Foulk WT et al. Bile duct carcinoma associated with ulcerative colitis. Rev Surg 1976; 33:289-293
5. Olsson R, Hulthen L. Concurrence of ulcerative colitis and chronic active hepatitis. Clinical courses and results of colectomy. Scand J Gastroenterol 1975; 10:331-334
6. Schrumpf E, Elgjo K, Fausa O et al. Sclerosing cholangitis in ulcerative colitis. Scand J Gastroenterol 1980; 15:689-697
7. Wewer V, Gluud C, Schlichting P et al. Prevalence of hepatobiliary dysfunction in a regional group of patients with chronic inflammatory bowel disease. Scand J Gastroenterol 1991; 26:97-102
8. Rasmussen HH, Fallingborg JF, Mortensen PB et al. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn's disease. Scand J Gastroenterol 1997; 32:604-610
9. Shepherd HA, Selby WS, Chapman RW et al. Ulcerative colitis and persistent liver dysfunction. Q J Med 1983; 52:503-513
10. Broome U, Glaumann H, Hellers G et al. Liver disease in ulcerative colitis: an epidemiological and follow up study in the county of Stockholm. Gut 1994; 35:84-89
11. Heikius B, Niemela S, Lehtola J et al. Hepatobiliary and coexisting pancreatic duct abnormalities in patients with inflammatory bowel disease. Scand J Gastroenterol 1997; 32:153-161
12. Mikkola K, Kiviluoto T, Riihela M et al. Liver involvement and its course in patients operated on for ulcerative colitis. Hepatogastroenterology 1995; 42:68-72
13. Boberg KM, Schrumpf E, Fausa O et al. Hepatobiliary disease in ulcerative colitis. An analysis of 18 patients with hepatobiliary lesions classified as smallduct primary sclerosing cholangitis. Scand J Gastroenterol 1994; 29:744-752
14. Perrett AD, Higgins G, Johnston HH et al. The liver in ulcerative colitis. Q J Med 1971; 40:211-238
15. de Fazio C, Torgano G, de Franchis R et al. Detection of liver involvement in inflammatory bowel disease by abdominal ultrasound scan. Int J Clin Lab Res 1992; 21:314-317
16. Riegler G, D'Inca R, Sturniolo GC et al. Hepatobiliary alterations in patients with inflammatory bowel disease: a multicenter study. Scand J Gastroenterol 1998; 33:93-98
17. Ozdil S, Akyuz F, Pinarbasi B et al. Ulcerative colitis: analyses of 116 cases (do extra intestinal manifestations Effect the time to catch remission? Hepatogastroenterology 2004; 51:768-770
18. Gisbert JP, Luna M, González-Lama Y et al. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis 2007; 13:1106-1114
19. Chapman RWG, Arborg BAM, Rhodes JM et al. Primary sclerosing cholangitis; a review of its clinical features, cholangiography and hepatic histology. Gut 1980; 21:870-877
20. Shen B, Achkar JP, Connor JT et al. Modified pouchitis disease activity index: a simplified approach to the diagnosis of pouchitis. Dis Colon Rectum 2003; 46:748-753
21. Shen B, Fazio VW, Remzi FH et al. Risk factors for diseases of ileal pouch-anal anastomosis after restorative proctocolectomy for ulcerative colitis. Clin Gastroenterol Hepatol 2006; 4:81-89 (Pubitemid 43129528)
22. Thomas CH. Ulceration of the colon with a much enlarged fatty liver. Trans Pathol Soc (Philadelphia) 1873; 4:87-88
23. Farrant JM, Hayllar KM, Wilkinsson ML et al. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991; 100:1710-1717
24. Olsson R, Danielsson A, Jarnerot G et al. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 1991; 100:1319-1323
25. Bargiggia S, Maconi G, Elli M et al. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. J Clin Gastroenterol 2003; 36:417-420
26. Blain A, Cattan S, Beaugerie L et al. Crohn's disease clinical course and severity in obese patients. Clin Nutr 2002; 21:51-57
27. Gisbert JP, Gonzalez-Lama Y, Mate J. Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol 2007; 102:1518-1527 (Pubitemid 46976279)
28. Bastida G, Nos P, Aguas M et al. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Aliment Pharmacolther 2005; 22:775-782
29. Dew MJ, Thompson H, Allan RN. The spectrum of hepatic dysfunction in inflammatory bowel disease. Q J Med 1979; 148:113-115
30. Bengoa JM, Hanauer SB, Sitrin MD et al. Pattern and prognosis of liver function tests abnormalities during parenteral nutrition in inflammatory bowel disease. Hepatology 1985; 5:79-84
31. Shen B, Remzi FH, Nutter B et al. Association between immune-associated disorders and adverse outcomes of ileal pouch-anal anastomosis. Am J Gastroenterol 2009; 104:655-64.